<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="32003">Pimobendan</z:chebi> (Vetmedin) is an effective treatment for canine <z:hpo ids='HP_0011010'>chronic</z:hpo> degenerative <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> and <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In an off-label use, it may also be of benefit for the treatment of <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> in dogs </plain></SENT>
<SENT sid="2" pm="."><plain>In this report, we describe the effects of a palatable customized oral form of <z:chebi fb="0" ids="32003">pimobendan</z:chebi> used with both compounded and commercially manufactured conventional drug therapy to treat degenerative <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> and <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> in two small dogs </plain></SENT>
<SENT sid="3" pm="."><plain>For those patients, who resisted many types of oral medication, the standard manufactured dose of <z:chebi fb="0" ids="32003">pimobendan</z:chebi> was inappropriate </plain></SENT>
<SENT sid="4" pm="."><plain>Formulations of the preparations used to treat the patients described in this report are provided for easy reference </plain></SENT>
<SENT sid="5" pm="."><plain>It should be noted that at the time of this writing, Boehringer Ingelheim GmbH (Ingelheim am Rhein, Germany), the manufacturer of <z:chebi fb="0" ids="32003">pimobendan</z:chebi>, has expressed concern about the stability of that agent in aqueous compounded form </plain></SENT>
<SENT sid="6" pm="."><plain>To our knowledge, no current data confirming the stability or bioequivalence of compounded <z:chebi fb="0" ids="32003">pimobendan</z:chebi> exist </plain></SENT>
</text></document>